174
Participants
Start Date
February 3, 2017
Primary Completion Date
February 1, 2022
Study Completion Date
July 8, 2025
Evorpacept (ALX148)
Evorpacept (ALX148)
Pembrolizumab
Keytruda
Trastuzumab
Herceptin
Rituximab
Rituxan
Ramucirumab + Paclitaxel
Standard of care chemotherapy
5-FU + Cisplatin
Standard of care chemotherapy
START-Midwest, Grand Rapids
University of Colorado Denver, Denver
Seattle Cancer Care Alliance, Seattle
Yale University, New Haven
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Seoul National University Bundang Hospital, Seongnam
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University, Seoul
Lead Sponsor
ALX Oncology Inc.
INDUSTRY